Registry for patients with cardiomyopathies
TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)
This study is collecting health information and samples from people with different types of heart muscle diseases to better understand their causes and effects over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2040 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Heidelberg, Baden-Wurttemberg) |
| Trial ID | NCT04265040 on ClinicalTrials.gov |
What this trial studies
The DZHK TORCH-Plus registry is designed to collect clinical data and biological samples from patients with various types of non-ischemic cardiomyopathies. This multi-center initiative aims to expand the existing registry by increasing the number of participants to better understand the prevalence and characteristics of these conditions. The study includes four main modules focusing on clinical phenotyping, genomics, inflammation, and biomarkers, which will facilitate innovative research in cardiomyopathies. Patients will be followed over time to gather comprehensive data on their health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults aged 18 to 80 diagnosed with non-ischemic structural cardiomyopathies.
Not a fit: Patients under 18 or over 80 years old, or those with other significant cardiac illnesses, may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved understanding and treatment options for patients with cardiomyopathies.
How similar studies have performed: Other similar registries have shown success in advancing knowledge and treatment of cardiomyopathies, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-ischemic structural cardiomyopathies * Age ≥ 18 or ≤ 80 years * The patient is able to understand the declaration of consent and to sign it dated * At least one of the following diagnoses depending on the specific TORCH- Plus inclusion / exclusion - SOP: Dilated Cardiomyopathy (DCM) * family / genetic * inflammatory / persistent myocarditis * idiopathic (after exclusion secondary cause) * left sided systolic dysfunction (EF ≤ 45%) Left ventricular hypertrophy * sarcomere hypertrophic cardiomoypathia (HCM, HOCM) * amyloid (AL: light chains, TTR: transthyretin, wild type) Left ventricular non-compaction cardiomyopathy (LVNC) Arrhythmogenic right ventricular cardiomyopathy (ARVC / D) Exclusion Criteria: The following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion / exclusion - SOP in detail: * Age: \<18 years or\> 80 years * Patient has other (cardiac) previous illnesses: * uncontrollable arterial hypertension * primary pulmonary arterial hypertension * radiation therapy in the chest area * addiction (drug or alcohol abuse) * life expectancy \<1 year due to non-cardiological pre-existing conditions * significant heart valve disease * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly) * chemotoxic cardiomyopathy * condition after myocarditis * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus) * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV) * Tachymyopathy
Where this trial is running
Heidelberg, Baden-Wurttemberg
- University Hospital Heidelberg - Clinic of Cardiology, Angiology and Pneumology — Heidelberg, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Study coordinator: Farbod Sedaghat-Hamendani, Dr.
- Email: Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de
- Phone: +496221/56-8676
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.